A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. (Q51549127)

6 April 2018

title

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. (English)

1 reference

6 April 2018

main subject

phase II clinical trial

0 references

tanespimycin

1 reference

ChEBI release 2020-05-28

1 reference

4

1 reference

6 April 2018

Paul Workman

12

object named as

Paul Workman

1 reference

6 April 2018

1

Simon Pacey

1 reference

6 April 2018

author name string

Martin Gore

2

1 reference

6 April 2018

David Chao

3

1 reference

6 April 2018

James Larkin

5

1 reference

6 April 2018

Sarah Sarker

6

1 reference

6 April 2018

Karen Owen

7

1 reference

6 April 2018

Yasmin Asad

8

1 reference

6 April 2018

Florence Raynaud

9

1 reference

6 April 2018

Mike Walton

10

1 reference

6 April 2018

Ian Judson

11

1 reference

6 April 2018

Tim Eisen

13

1 reference

6 April 2018

publication date

5 August 2010

1 reference

6 April 2018

Investigational New Drugs

published in

1 reference

6 April 2018

volume

30

1 reference

6 April 2018

issue

1

1 reference

6 April 2018

page(s)

341-349

1 reference

6 April 2018

https://scigraph.springernature.com/pub.10.1007/s10637-010-9493-4

exact match

0 references

cites work

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Inhibitors of the heat shock response: biology and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Telomerase as a Target for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Chemotherapy for metastatic melanoma: time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Targeting Hsp90: small-molecule inhibitors and their clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9493-4

Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma

21 January 2018

1 reference

12 December 2020

Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties

1 reference

12 December 2020

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts

1 reference

12 December 2020

Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET

1 reference

12 December 2020

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

1 reference

12 December 2020

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

1 reference

12 December 2020

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

1 reference

12 December 2020

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

1 reference

12 December 2020

Evaluation of response: new and standard criteria

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

1 reference

12 December 2020

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

12 December 2020

In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors

1 reference

12 December 2020

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

1 reference

12 December 2020

10.1007/S10637-010-9493-4

Identifiers

DOI

1 reference

6 April 2018

PubMed ID

20683637

1 reference

6 April 2018